IPP Bureau
Belite Bio reports landmark phase 3 success for Stargardt Disease therapy
By IPP Bureau - December 03, 2025
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea
By IPP Bureau - December 03, 2025
Presbyopia, the age-related loss of near vision, could soon be treated successfully
WHO urges rapid expansion of new HIV prevention tools amid funding crisis
By IPP Bureau - December 03, 2025
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval
By IPP Bureau - December 03, 2025
Now a test that offers new precision in prostate cancer detection
FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich
By IPP Bureau - December 02, 2025
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers
By IPP Bureau - December 02, 2025
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Lilly slashes prices on Zepbound vials to expanding access to obesity treatment
By IPP Bureau - December 02, 2025
Patients can now get the starting 2.5 mg dose for $299 per month
Bayer welcomes US Solicitor General’s support as Supreme Court weighs Roundup case
By IPP Bureau - December 02, 2025
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis
By IPP Bureau - December 01, 2025
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Lupin receives FDA approval for biosimilar Armlupeg
By IPP Bureau - December 01, 2025
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Roche expands Veeva partnership with global rollout of AI-driven Vault CRM
By IPP Bureau - December 01, 2025
Roche says the move marks a step forward in its digital transformation strategy
OSR Holdings moves towards major licensing deal for oral cancer immunotherapy
By IPP Bureau - December 01, 2025
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
LANXESS unveils next-gen biosecurity solutions for Indian poultry market at Poultry Expo
By IPP Bureau - December 01, 2025
LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments
Sudapack breaks ground on major PharmaGuard expansion in Erolzheim
By IPP Bureau - December 01, 2025
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
Global measles deaths plunge but cases surge, says WHO
By IPP Bureau - December 01, 2025
In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
